Kyowa Kirin Co Ltd 2023 IR
The report highlights Kyowa Kirin's progress in FY2023 toward its Vision 2030, achieving record financial results with revenue of ¥442.2 billion and a return on equity of 10.2%. The company advanced its global specialty pharmaceutical strategy by acquiring Orchard Therapeutics to integrate hematopoietic stem cell gene therapy into its pipeline. In sustainability, Kyowa Kirin reduced its annual CO2 emissions by approximately 55% compared to 2019 through the transition to RE100-compliant renewable energy at major Japanese sites. Additionally, the company launched proprietary sales of Crysvita in North America and established a joint venture with Grünenthal to focus resources on its core global medicines.
Company: Kyowa Kirin Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 67
Kyowa Kirin Co Ltd
Integrated Report
The report highlights Kyowa Kirin's progress in FY2023 toward its Vision 2030, achieving record financial results with revenue of ¥442.2 billion and a return on equity of 10.2%. The company advanced its global specialty pharmaceutical strategy by acquiring Orchard Therapeutics to integrate hematopoietic stem cell gene therapy into its pipeline. In sustainability, Kyowa Kirin reduced its annual CO2 emissions by approximately 55% compared to 2019 through the transition to RE100-compliant renewable energy at major Japanese sites. Additionally, the company launched proprietary sales of Crysvita in North America and established a joint venture with Grünenthal to focus resources on its core global medicines.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 2023 - Dec 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women in Management
Net Zero Target
Employees